<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;
	font-weight:normal;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-GB>

<div class=WordSection1>

<h1><span lang=EN-US>2019B14 Discuss the role of paracetamol in multi-modal
analgesia (33%). Explain paracetamol metabolism and the mechanism of toxicity
(67%). DO NOT discuss management of toxicity.</span></h1>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US>List:</span></h3>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Mechanism</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Role</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Metabolism</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Toxicity</span></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US>Mechanism:</span></h3>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>↑5HT activity -&gt; ↑descending modulation
(multiple receptor subtypes involved)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Endocannabinoid reuptake inhibition -&gt;
central analgesia, tranquility (paracetamol’s active CNS metabolite AM404)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Central COX inhibition: unclear effect and
significance</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Other: nitric oxide, opioid pathways</span></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US>Role:</span></h3>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>First step in the WHO analgesic ladder</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Minimal side effects, low risk of toxicity</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Reduces opioid use and opioid side effects</span></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US>Metabolism:</span></h3>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Phase 2</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Glucuronidation ~55%</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Sulfation ~35%</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Phase 1</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>CYP450 to NAPQI (N-acetyl P-benzquinonimine)
~10%</span></p>

<h3><span lang=EN-US>Toxicity:</span></h3>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>With normal doses</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>NAPQI + glutathione -&gt; cysteine conjugate,
mercaptopuric acid conjugate</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>With high dose</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Conjugation pathways saturated</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>↑NAPQI production</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Glutathione exhausted (earlier if malnourished)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>↑NAPQI accumulation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Damage to hepatic proteins</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Centrilobular necrosis</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;text-indent:-.25in'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Acute liver failure</span></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
